Understanding RUFY3: A Potential Drug Target Or Biomarker (G22902)
Understanding RUFY3: A Potential Drug Target Or Biomarker
RUFY3 (RUFY3_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, kidneys, and liver. It is a member of the superfamily of RNA-binding proteins, known as RUFY proteins, which are characterized by their ability to interact with RNA molecules.
RUFY3 is of particular interest as a potential drug target or biomarker because of its involvement in a number of important cellular processes. For example, it has been shown to play a role in the regulation of gene expression, cell signaling, and the development of cancer.
One of the key functions of RUFY3 is its ability to interact with RNA molecules. This interaction occurs through a protein called RUFY3-interacting RNA, which is a stable complex of the protein and a small RNA molecule known as hnRNA. This complex plays a role in the regulation of gene expression by binding to specific target genes and affecting their levels of expression.
In addition to its role in gene expression, RUFY3 is also involved in the regulation of cellular signaling pathways. For example, it has been shown to play a role in the regulation of the T-cell receptor, a critical component of the immune system that plays a critical role in fighting off infections and diseases.
RUFY3 is also of interest as a potential biomarker because of its involvement in the development of cancer. Studies have shown that RUFY3 is highly expressed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, inhibition of RUFY3 has been shown to be effective in treating cancer in cell models.
Despite its potential as a drug target or biomarker, much more research is needed to fully understand the role of RUFY3 in cellular processes and its potential as a therapeutic agent. For example, it is not yet clear what the full range of effects of RUFY3 inhibition would be, or what the most effective way to target this protein would be.
In conclusion, RUFY3 is a protein that is of great interest as a potential drug target or biomarker due to its involvement in various cellular processes and its potential as a therapeutic agent in the treatment of cancer. Further research is needed to fully understand its role and potential as a therapeutic agent.
Protein Name: RUN And FYVE Domain Containing 3
Functions: Plays a role in the generation of neuronal polarity formation and axon growth (By similarity). Implicated in the formation of a single axon by developing neurons (By similarity). May inhibit the formation of additional axons by inhibition of PI3K in minor neuronal processes (By similarity). Plays a role in the formation of F-actin-enriched protrusive structures at the cell periphery (PubMed:25766321). Plays a role in cytoskeletal organization by regulating the subcellular localization of FSCN1 and DBN1 at axonal growth cones (By similarity). Promotes gastric cancer cell migration and invasion in a PAK1-dependent manner (PubMed:25766321)
More Common Targets
RUFY4 | RUNDC1 | RUNDC3A | RUNDC3A-AS1 | RUNDC3B | RUNX1 | RUNX1-IT1 | RUNX1T1 | RUNX2 | RUNX2-AS1 | RUNX3 | RUNX3-AS1 | RUSC1 | RUSC1-AS1 | RUSC2 | RUSF1 | RUVBL1 | RUVBL1-AS1 | RUVBL2 | RWDD1 | RWDD2A | RWDD2B | RWDD3 | RWDD3-DT | RWDD4 | RXFP1 | RXFP2 | RXFP3 | RXFP4 | RXRA | RXRB | RXRG | RXYLT1 | Ryanodine receptor | RYBP | RYK | RYR1 | RYR2 | RYR3 | RZZ complex | S100 Calcium Binding Protein | S100A1 | S100A10 | S100A11 | S100A11P1 | S100A12 | S100A13 | S100A14 | S100A16 | S100A2 | S100A3 | S100A4 | S100A5 | S100A6 | S100A7 | S100A7A | S100A7L2 | S100A7P1 | S100A8 | S100A9 | S100B | S100G | S100P | S100PBP | S100Z | S1PR1 | S1PR1-DT | S1PR2 | S1PR3 | S1PR4 | S1PR5 | SAA1 | SAA2 | SAA2-SAA4 | SAA3P | SAA4 | SAAL1 | SAC3D1 | SACM1L | SACS | SACS-AS1 | SAE1 | SAFB | SAFB2 | SAG | SAGA complex | SAGE1 | SALL1 | SALL2 | SALL3 | SALL4 | SALL4P7 | SALRNA2 | SAMD1 | SAMD10 | SAMD11 | SAMD12 | SAMD12-AS1 | SAMD13 | SAMD14